GCK

Detailed Insights on Glucokinase - H2 2020 Pipeline Review - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 6, 2021

The "Glucokinase - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Glucokinase - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) pipeline Target constitutes close to 14 molecules.
  • The latest report Glucokinase - Pipeline Review, H2 2020, outlays comprehensive information on the Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Glucokinase is an enzyme that catalyzes the initial step in utilization of glucose by the beta-cell and liver at physiological glucose concentration.

Glucokinase - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 20, 2020

The "Glucokinase - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Glucokinase - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Hepatic glucokinase helps to facilitate the uptake and conversion of glucose by acting as an insulin-sensitive determinant of hepatic glucose usage.
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) pipeline Target constitutes close to 11 molecules.
  • The latest report Glucokinase - Pipeline Review, H2 2019, outlays comprehensive information on the Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Glucokinase Pipeline Review Report, H2 2019 - Analysis by Indication, Stage of Development, Mechanism of Action, Route of Administration and Molecule Type

Retrieved on: 
Tuesday, January 14, 2020

DUBLIN, Jan. 14, 2020 /PRNewswire/ -- The "Glucokinase - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 14, 2020 /PRNewswire/ -- The "Glucokinase - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report outlays comprehensive information on the Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • It also reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics development with respective active and dormant or discontinued projects.
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    Featured News & Press Releases, 2019
    Nov 11, 2019: Hua Medicine's pivotal phase III monotherapy trial of dorzagliatin, a dual-acting glucokinase modulator, achieves primary efficacy endpoint in patients with type 2 diabetes
    Jan 16, 2019: vTv Therapeutics announces publication of comprehensive data in Science Translational Medicine detailing the discovery and clinical development of TTP399, including results of phase 2 AGATA study